Veterinary Medicine Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Veterinary Medicine Market Trends and Insights

Rising Chronic Animal Diseases & Pet Ownership

Pet-ownership levels climbed to 67% of U.S. households in 2024 and continue to rise, while chronic conditions now affect approximately 40% of dogs older than seven years.^{[1]American Veterinary Medical Association, “U.S. Pet Ownership Statistics,” avma.org} The annual spend per companion animal reached USD 1,620 in 2025, a 12% year-over-year increase, as owners opt for long-term disease management over euthanasia. Four-point-four million pets carried insurance in North America by the end of 2025, shifting more out-of-pocket risk to insurers and enabling the uptake of premium biologics. China, with a population of over 200 million pets in 2025, mirrors these patterns as urban millennials allocate 15% of their disposable income to pet care. The resulting demand underscores a durable driver for the veterinary medicine market across both mature and emerging economies.

Industrialised Livestock Expansion

China rebuilt its swine herd to 450 million head by mid-2025 under biosecurity rules that require trivalent vaccines, triggering sustained demand for porcine biologics.^{[2]USDA Foreign Agricultural Service, “Livestock and Poultry: World Markets and Trade,” usda.gov} India’s layer-hen capacity increased by 8% between 2024 and 2025, resulting in the production of 52 billion eggs, which subsequently raised demand for respiratory vaccines. Brazil’s 234 million-head cattle sector is trialing methane-reducing feed additives that also improve weight gain, thereby boosting therapeutic volumes. Vietnam’s aquaculture producers lowered antibiotic use by 22% in 2025 by adopting autogenous vaccines. Together, these developments serve as a long-term catalyst for the veterinary medicine market, as producers shift from growth-promoting antibiotics to preventive platforms.

Regulatory Antibiotic-Stewardship Push for Vaccines/Biologics

EU Regulation (EU) 2019/6, which prohibits the use of prophylactic antibiotics in livestock, came into full force in 2024.^{[3]European Medicines Agency, “Veterinary Medicinal Products Regulation,” ema.europa.eu} In the United States, FDA Guidance 263 was issued in 2025, removing the remaining over-the-counter livestock antibiotics. China banned colistin feed additives and will mandate electronic prescriptions by 2026. Compliance costs averaged EUR 8,500 per EU farm in 2025, nudging smallholders toward consolidators. These policy moves divert investment to vaccines, probiotics, and organic acids, lifting the preventive-care contribution to the veterinary medicine market.

Break-Through MAbs & Gene-Based Therapies Approvals

The FDA granted conditional approval for Librela in cats in 2024, and the earlier canine version, which validated MAb pain control, was priced at USD 90-120 per month, compared to triple generic NSAIDs. Elanco’s Credelio Plus won EMA clearance in 2025, combining flea, tick, and heartworm protection in one dose. Boehringer Ingelheim’s gene-deleted African swine fever vaccine entered Phase III trials after proving 94% efficacy. Ceva’s recombinant fowlpox vector vaccine launched in Latin America in 2025, broadening DIVA-capable poultry immunization. These milestones highlight the increasing share of biologics in the veterinary medicine market.

High Cost of Advanced Veterinary Care & Diagnostics

MRI scans cost USD 2,500-3,500 in the United States in 2025, discouraging 40% of uninsured owners from pursuing advanced imaging. Cytopoint therapy for a 30-kg dog costs USD 1,080-1,440 per year, while generic steroids total USD 180, creating adherence gaps. South American cattle operations earn margins below USD 50 per head, making USD 2 vaccines unviable unless mortality risk is severe. Small Indian dairy farmers spend under USD 12 annually per cow, relying on subsidized campaigns. High price points, therefore, constrain premium uptake, tempering expansion of the veterinary medicine market.

Stringent Multi-Region Regulatory Pathways

Veterinary approvals take an average of 7.2 years in the United States, longer than for human drugs, because safety trials span multiple species. EMA procedures can extend to 8.5 years when arbitration is involved. China’s 2024 biologics rules add domestic trials even for already-approved Western products, adding 18-24 months and USD 3-5 million in costs. Divergent residue limits require reformulation or market exit. Smaller companies struggle to navigate the complexity, dampening competitive diversity within the veterinary medicine market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Biologics Gain as Antibiotics Face Regulatory Headwinds

Drugs controlled a 57.11% share in 2025, but vaccines are on track for a 10.62% CAGR, a pivot that mirrors antibiotic-stewardship mandates. Parasiticides, such as NexGard and Credelio, generated more than USD 1 billion combined in 2025, buoyed by warming climates that extend flea and tick seasons. Anti-infective sales declined 18% year-over-year in Europe, as the use of fluoroquinolones and cephalosporins decreased. Recombinant vaccines offer DIVA capability, and Zoetis’s Fostera Gold PCV MH earned USD 180 million in 2025 by bundling protection against two porcine pathogens. Amino-acid feed additives expanded by 9% as producers sought growth promotion without antibiotics.

By Animal Type: Livestock Industrialization Narrows Companion-Animal Lead

Companion animals accounted for 55.93% of 2025 revenue; however, livestock treatments are projected to have a 12.26% CAGR, a rate that will progressively narrow the gap. Dogs represented 62% of companion-animal turnover thanks to higher dosing volumes and a greater orthopedic surgery burden. Cats followed at 32%, boosted by feline-specific biologics such as Solensia. Cattle remain the largest livestock spenders by absolute value. Yet, poultry is expected to grow fastest as China, India, and the United States vaccinate billions of birds at a minimal per-dose cost. The swine sector's recovery from African swine fever has led to high vaccine uptake, reaching 78% of commercial farms by 2025.

By Mode of Delivery: Topical Gains as Owner Administration Rises

Parenteral products accounted for 47.88% of sales in 2025, but topical revenues are projected to grow at a 10.06% CAGR through 2031. Owner-applied parasiticides, such as Frontline and Advantage, together generated USD 340 million in 2025, with the convenience of once-monthly applications driving compliance. Oral chewables accounted for 38% of the 2025 turnover, led by heartworm and flea preventives, which achieved a 94% palatability acceptance rate. Transdermal offerings remain rare due to fur interference and variability in absorption, which limits category expansion. Automated injection in poultry operations sliced labor costs to USD 0.08 per bird, anchoring parenteral dominance in industrial livestock.

By End User: Clinics Gain Share as Telemedicine Routes Prescriptions

Veterinary hospitals owned 58.14% of the 2025 spend, underpinned by 24-hour emergency and surgical capabilities. Clinics, numbering about 28,000 in the United States, are set for a 12.75% CAGR through 2031, propelled by telehealth partnerships that funnel prescription volumes without in-person exams. Home-care settings captured 18% of 2025 revenue as owners administered chronic treatments purchased online. Corporate consolidators expanded footprints and negotiated 15-20% pharmaceutical discounts, widening margin advantages. Research institutes kept 4% of spending, supporting 42 investigational new animal drug studies in 2025.

Geography Analysis

North America generated 41.46% of the 2025 revenue, driven by 85 million U.S. pet households and an annual per-pet spend exceeding USD 1,500. The region’s regulatory emphasis on antimicrobial stewardship pushes vaccine adoption, while e-pharmacy leadership expands access. Europe captured 28% of 2025 sales as pet insurance coverage exceeded 25% in the United Kingdom and Sweden, stabilizing out-of-pocket expenses. Regulation (EU) 2019/6 reinforces the use of preventive biologics, and pain-management rules increase analgesic uptake in livestock.

The Asia-Pacific region is poised for an 11.86% CAGR and is gradually challenging North American dominance as China rebuilds its hog herd and India scales up poultry capacity. Rising urban disposable incomes lift companion-animal demand; tier-1 Chinese cities alone counted 121 million pets in 2025. Cold-chain gaps remain a constraint; however, domestic biologics manufacturing investments are ramping up, signaling a long-term upside for the veterinary medicine market.

South America contributed 9% of 2025 turnover, chiefly from Brazil’s 234 million-head cattle herd; however, per-animal spend lags global averages because producers favor generics. Middle East & Africa held 6%, with equine therapeutics in GCC countries and South African vaccines against foot-and-mouth disease anchoring demand. Regional growth prospects depend on improving cold-chain infrastructure and gains in purchasing power.

Regulatory Landscape

Veterinary medicines regulation continues to tighten around antimicrobial stewardship, residues, and pharmacovigilance across major markets. In the European Union, Regulation (EU) 2019/6 remains the core framework governing marketing authorizations and post-market surveillance, with the European Medicines Agency (EMA) and its Committee for Veterinary Medicinal Products (CVMP) steering 2026 work priorities. These priorities include facilitating development via veterinary scientific advice and maintaining updates tied to maximum residue limits (MRLs). The practical effect is a continued shift from routine antibiotic use toward preventive vaccines, recombinant platforms, and other alternatives aligned with food-chain compliance needs.

In the United States, the FDA Center for Veterinary Medicine (CVM) continues to manage approvals and policy under the Federal Food, Drug, and Cosmetic Act, with FY 2026 animal drug user fee rates (ADUFA/AGDUFA) in effect through September 30, 2026, shaping sponsor budgeting and review planning. The FDA also issued final Guidance for Industry (GFI) #96 in June 2026 on anthelmintic effectiveness for ovines, reinforcing method and evidence expectations in parasiticide development. In Great Britain, the Veterinary Medicines (Amendment etc.) Regulations 2024 (in force May 2024) updated domestic requirements post-Brexit. Government guidance also flags a new SPS agreement targeted for mid-2027, with further business guidance expected in autumn 2026, which adds compliance planning complexity for manufacturers and distributors serving UK and EU supply routes.

Value Chain Analysis

The veterinary medicine value chain spans discovery and multi-species development, regulatory submission and review, GMP manufacturing (including sterile biologics and cold-chain-dependent vaccines), and route-to-market through specialized animal health distributors and veterinary providers. Upstream dependencies include APIs, excipients, packaging, and biologics inputs, while midstream operations depend on validated quality systems that can withstand regulator inspections across jurisdictions. Downstream, manufacturers rely on veterinary hospitals and clinics for prescribing and administration, alongside e-pharmacy and home-care channels that are expanding access for chronic therapies. Even with that access, exclusivity arrangements and channel rules can still limit product availability in some markets.

Distribution and service layers are consolidating into broader platforms that bundle logistics, practice technology, diagnostics, and replenishment programs, tightening control over inventory flow and customer capture. 2026 deal activity highlights the pull toward integrated platforms: Covetrus and MWI Animal Health announced a merger to combine distribution and technology platforms, while Zoetis pursued capability additions in diagnostics and precision animal health through acquisitions. At the same time, manufacturing delays, API and raw material constraints, and higher compliance burdens for international facilities continue to create episodic shortages. These constraints also push prioritization toward higher-volume SKUs, particularly for cold-chain biologics and specialty products.

Market Opportunities and Future Outlook

Biologics capacity buildout and specialized vaccine manufacturing create visible whitespace for improving supply resilience and access, particularly for recombinant and autogenous vaccines that require tighter GMP controls. Merck Animal Healths USD 895 million investment announced in May 2025 to expand manufacturing and R&D in De Soto, Kansas, focused on large-molecule vaccines and biologics, and Cevas planned new 7,000 m2 vaccine plant at Ceva Phylaxia in Monor, Hungary (scheduled for operation at end-2026) highlight ongoing scaling in high-barrier categories. Dopharma and Ripac-Labor also advanced a new autogenous vaccine production facility in Potsdam, Germany, with an end-2026 commissioning target, supporting an opportunity set around farm-specific solutions where antimicrobial stewardship and biosecurity programs tighten.

Precision animal health and clinic productivity tools offer another opportunity lane as diagnostics and digital workflows become more embedded in prescribing and monitoring. The 2026 acquisition activity by Zoetis in diagnostics and genomics (VitalRADS and Neogens animal genomics business) illustrates a commercial push to connect testing, data, and therapeutics, which can improve targeting of parasiticides, pain biologics, and chronic-care regimens in companion animals. It also supports herd-level decisions in production animals. On the public-private side, the European Partnership on Animal Health and Welfare launched in 2024 with a EUR 360 million, seven-year budget provides a structured vehicle for collaborative R&D and data-driven animal health programs, reinforcing demand for validated vaccine platforms, residue-compliant treatments, and surveillance-linked products that fit modern stewardship policies.